Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senna and carcinogenicity

This article was originally published in The Tan Sheet

Executive Summary

Purdue Pharma will amend and submit its final report on a two-year oral carcinogenicity study in rats to support the safety of senna-containing OTC laxatives by end of March 2004, company states in recent letter to FDA. Agency requested the completion of histopathological examinations of the brain tissues from the remaining animals of the low- and mid-dose groups in an Oct. 21. letter to the company. Purdue will evaluate 33 rats in its follow up examination. "It must be noted that the protocol for this study was reviewed and accepted by the Carcinogenicity Assessment Committee [and] this additional analysis was not required according to the protocol," Purdue states in the letter...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel